OnKure Therapeutics (NASDAQ:OKUR – Free Report) – Research analysts at Lifesci Capital issued their FY2025 earnings per share estimates for OnKure Therapeutics in a note issued to investors on Tuesday, March 11th. Lifesci Capital analyst S. Slutsky forecasts that the company will post earnings per share of ($5.14) for the year. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share.
OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) last announced its quarterly earnings data on Monday, March 10th. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.51).
Read Our Latest Stock Analysis on OKUR
OnKure Therapeutics Price Performance
OKUR stock opened at $4.62 on Thursday. The business’s 50 day simple moving average is $5.82. The firm has a market cap of $15.44 million, a price-to-earnings ratio of -0.38 and a beta of 0.28. OnKure Therapeutics has a 1-year low of $4.55 and a 1-year high of $20.00.
Hedge Funds Weigh In On OnKure Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the business. Acorn Capital Advisors LLC bought a new position in OnKure Therapeutics during the 4th quarter valued at approximately $12,381,000. Citadel Advisors LLC bought a new position in shares of OnKure Therapeutics during the fourth quarter valued at approximately $8,782,000. Samsara BioCapital LLC purchased a new stake in OnKure Therapeutics in the fourth quarter worth $7,088,000. Vestal Point Capital LP bought a new stake in OnKure Therapeutics in the fourth quarter valued at $5,461,000. Finally, Deep Track Capital LP purchased a new position in OnKure Therapeutics during the 4th quarter valued at $4,506,000. Institutional investors own 90.98% of the company’s stock.
OnKure Therapeutics Company Profile
OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.
See Also
- Five stocks we like better than OnKure Therapeutics
- Want to Profit on the Downtrend? Downtrends, Explained.
- 3 Undervalued Stocks You Can Buy at a Discount Now
- The Risks of Owning Bonds
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- What is MarketRank™? How to Use it
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for OnKure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OnKure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.